AI辅助口服小分子新药研发，「知维拓」获数千万元种子轮融资｜早起看早期

Core Insights - Riltide Medicines has completed a seed round financing of several million RMB, led by Newerly Capital and followed by Qingtan Investment, to advance its core pipeline in preclinical research and develop an AI interactive molecular design platform [3][4] - The company focuses on the development of innovative oral small molecule drugs targeting autoimmune diseases such as systemic lupus erythematosus and inflammatory bowel disease [3][4] - The founder and CEO, Long Wei, has nearly 20 years of experience in drug research and management, previously holding senior positions in other pharmaceutical companies [3] Company Strategy - Riltide Medicines aims to leverage advancements in AI technology to enhance drug discovery processes, particularly in the field of oral small molecule drugs, which are becoming increasingly important in autoimmune disease treatment [4][5] - The company has developed its own EnCore AI interactive design platform to accelerate the discovery of lead compounds and improve molecular optimization efficiency [4][5] Market Potential - Investors express confidence in Riltide Medicines' strategic direction in developing oral small molecule drugs for autoimmune diseases, highlighting the significant demand potential in this area [6] - The integration of AI in drug design is seen as a key factor that could enable the company to explore globally competitive product projects [6]